Comparative Pharmacology
Head-to-head clinical analysis: LEVOCETIRIZINE HYDROCHLORIDE versus ZYRTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOCETIRIZINE HYDROCHLORIDE versus ZYRTEC.
LEVOCETIRIZINE HYDROCHLORIDE vs ZYRTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocetirizine is a selective peripheral histamine H1-receptor antagonist. It inhibits the effects of histamine at the H1 receptor, reducing allergic symptoms such as itching, sneezing, and rhinorrhea. It has lower affinity for central H1 receptors and anticholinergic properties compared to first-generation antihistamines.
Selective histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
Oral, 5 mg once daily in the evening.
5-10 mg orally once daily; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life: 7–8 hours in healthy adults; prolonged to 20–24 hours in renal impairment (CrCl <40 mL/min); clinically, stable levels require 2–3 days.
Terminal elimination half-life is approximately 8-11 hours in healthy adults, prolonged in renal impairment (e.g., up to 20 hours in moderate renal failure).
Approximately 85% renal excretion as unchanged drug via glomerular filtration and tubular secretion, 12.9% fecal excretion, <1% biliary.
Cetirizine is primarily excreted unchanged in urine (approximately 70% renal elimination) and feces (about 10%).
Category A/B
Category C
Antihistamine
Antihistamine